# Comparing Efficacy and Safety of CinnaGen Biosimilar Growth Hormone (CinnaTropin®) Versus Nordilet in Children With Idiopathic Growth Hormone Deficiency

> **NCT03223025** · PHASE3 · COMPLETED · sponsor: **Cinnagen** · enrollment: 30 (actual)

## Conditions studied

- Idiopathic Growth Hormone Deficiency

## Interventions

- **DRUG:** CinnaTropin®
- **DRUG:** Nordilet®

## Key facts

- **NCT ID:** NCT03223025
- **Lead sponsor:** Cinnagen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03-09
- **Primary completion:** 2017-02-04
- **Final completion:** 2017-02-04
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2023-08-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03223025

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03223025, "Comparing Efficacy and Safety of CinnaGen Biosimilar Growth Hormone (CinnaTropin®) Versus Nordilet in Children With Idiopathic Growth Hormone Deficiency". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03223025. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*